NCT05509153View on ClinicalTrials.gov

A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

PHASE2RecruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

May 1, 2027

Conditions
Huntington Disease
Interventions
DRUG

NAC

1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day

DRUG

Placebo

Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day

Trial Locations (5)

2145

RECRUITING

Westmead Hospital, Westmead

3050

NOT_YET_RECRUITING

The Royal Melbourne Hospital, Parkville

3195

NOT_YET_RECRUITING

Calvary Health Care Bethlehem, Parkdale

4029

NOT_YET_RECRUITING

The University of Queensland, Herston

6009

NOT_YET_RECRUITING

Perron Institute, Nedlands

All Listed Sponsors
collaborator

Deakin University

OTHER

collaborator

Monash University

OTHER

collaborator

Royal Perth Hospital

OTHER

collaborator

The University of Queensland

OTHER

collaborator

University of Melbourne

OTHER

lead

Western Sydney Local Health District

OTHER